Gross Profit Analysis: Comparing Vertex Pharmaceuticals Incorporated and Corcept Therapeutics Incorporated

Vertex vs. Corcept: A Decade of Gross Profit Growth

__timestampCorcept Therapeutics IncorporatedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201425669000519428000
Thursday, January 1, 201548925000906794000
Friday, January 1, 2016792630001491717000
Sunday, January 1, 20171556470002213533000
Monday, January 1, 20182460320002638058000
Tuesday, January 1, 20193009820003615063000
Wednesday, January 1, 20203482920005469383000
Friday, January 1, 20213606970006670200000
Saturday, January 1, 20223964730007850400000
Sunday, January 1, 20234758940008607000000
Monday, January 1, 20249489600000
Loading chart...

Unleashing the power of data

Gross Profit Growth: Vertex vs. Corcept

In the competitive landscape of pharmaceuticals, understanding financial performance is crucial. This analysis compares the gross profit growth of Vertex Pharmaceuticals Incorporated and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Vertex Pharmaceuticals has demonstrated a remarkable growth trajectory, with its gross profit increasing by over 1,500%, reaching approximately $8.6 billion in 2023. In contrast, Corcept Therapeutics, while smaller in scale, has shown a steady increase of over 1,700%, culminating in a gross profit of around $476 million in 2023.

Vertex's robust growth can be attributed to its innovative treatments and strategic market positioning, while Corcept's consistent performance highlights its niche focus and effective management. This decade-long financial journey underscores the dynamic nature of the pharmaceutical industry, where strategic innovation and market adaptation are key to sustained growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025